Additionally, keeping in mind that patients’ harboring BRCA1/2 or HRR mutations are benefitted from conventional PARP-1 inhibitors, PARP-1 Auger therapy has the advantage that its use can be extended beyond BRCA1/2 defective cancers. Here, PARP1 is linked to cancer.